Compare iShares Core S&P 500 ETF (IVV) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core S&P 500 ETF vs Neurocrine Biosciences Inc — how do they compare? iShares Core S&P 500 ETF trades at $780.16 (market cap $897.20B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B). The key difference: iShares Core S&P 500 ETF is far larger — about 62.5× Neurocrine Biosciences Inc's market cap, and iShares Core S&P 500 ETF is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core S&P 500 ETF for 46 Days and Neurocrine Biosciences Inc for 23 Days on average.
| IVV | NBIX | |
|---|---|---|
Market Cap | $897.20B | $14.36B |
Volume | 4,580,672 | 1,237,180 |
Sector | Broad Market / Factor | Health |
52-Week High | $782.58 | $185.50 |
52-Week Low | $634.93 | $123.10 |
Typical Hold Time | 46 Days | 23 Days |
Enterprise Value | — | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IVV, tracking the S&P 500, trades at $780.6, down 0.25% on the day. Technical indicators show a bullish trend with strong moving average support, though RSI suggests potential overbought conditions near-term. The ETF benefits from diversified exposure to large-cap US equities, with recent news highlighting strong corporate earnings growth expectations of 35% for 2026. Market sentiment remains mixed amid concerns about valuation and profit growth normalization.
Outlook remains cautiously optimistic given the S&P 500's historical bullish seasonal patterns and strong institutional support. Key risks include elevated Treasury yields, concentration in top holdings, and potential earnings growth deceleration to 15% in 2027. The ETF's low-cost structure and broad market exposure provide defensive characteristics during market volatility.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core S&P 500 ETF
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
